Patents Assigned to Daiichi Sankyo Company, Limited
-
Patent number: 11208403Abstract: The present disclosure provides novel compounds or salts thereof, or crystals of the compounds or the salts, which inhibit Axl and are useful in the treatment of a disease caused by hyperfunction of Axl, the treatment of a disease associated with hyperfunction of Axl, and/or the treatment of a disease involving hyperfunction of Axl.Type: GrantFiled: September 18, 2019Date of Patent: December 28, 2021Assignee: Daiichi Sankyo Company, LimitedInventors: Noriyasu Haginoya, Takashi Suzuki, Miho Hayakawa, Masahiro Ota, Tomoharu Tsukada, Katsuhiro Kobayashi, Yosuke Ando, Takeshi Jimbo, Koichi Nakamura
-
Patent number: 11208442Abstract: The present invention provides a novel endo-?-N-acetylglucosaminidase that is isolated from a fungus belonging to the genus Rhizomucor and is active under high-temperature conditions; various mutant enzymes thereof; genes encoding the enzymes; a recombinant plasmid; a transformant transformed with the plasmid; and the like.Type: GrantFiled: December 1, 2017Date of Patent: December 28, 2021Assignee: Daiichi Sankyo Company, LimitedInventors: Hanako Ito, Yasunori Ono, Kensuke Nakamura
-
Publication number: 20210393601Abstract: An object of the present invention is to provide a combination drug having an EZH1/2 dual inhibitor in combination with another medical agent and exerting an excellent anticancer effect. Provided is a combination drug having an EZH1/2 dual inhibitor in combination with another medical agent and exerting an excellent anticancer effect.Type: ApplicationFiled: November 29, 2019Publication date: December 23, 2021Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventor: Daisuke HONMA
-
Publication number: 20210386865Abstract: A method for producing an antibody-drug conjugate composition, comprising: (i) a step of reacting an antibody with a reducing agent in a buffer to reduce interchain disulfides, and (ii) a step of reacting drug linker intermediates with the antibody having thiol groups obtained in the step (i), wherein the reaction temperature in the step (i) is ?10° C. to 10° C., and the average number of bound drugs in the produced antibody-drug conjugate composition is 3.5 to 4.5, and the content of antibody-drug conjugates in which four drug linkers are bound to heavy-light interchain thiols, in the produced antibody-drug conjugate composition is 50% or more; and an antibody-drug conjugate composition, wherein the content of antibody-drug conjugates wherein the average number of bound drugs is 3.5 to 4.5, and the content of antibody-drug conjugates in which four drug linkers are bound to heavy-light interchain thiols, is 50% or more.Type: ApplicationFiled: August 26, 2021Publication date: December 16, 2021Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Shigeru NOGUCHI, Ken SAKURAI, Daisuke OKAJIMA
-
Patent number: 11185594Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the formula: L1-L2-LP-NH—(CH2)n1-La-Lb-Lc or -L1-L2-LP- wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the terminal Lc or LP with the nitrogen atom of the amino group at position 1 as the connecting position.Type: GrantFiled: April 6, 2015Date of Patent: November 30, 2021Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Hideki Miyazaki, Yuji Kasuya, Koji Morita, Yusuke Ogitani, Yuki Abe
-
Publication number: 20210355087Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the following formula (I): wherein X1 represents a nitrogen atom or CR9, R1 represents a hydrogen atom, a C1-C6 alkyl group, or a C1-C6 alkoxy group, R2 represents a halogen atom, R3 represents a hydrogen atom or a halogen atom, R4 represents a hydrogen atom or a halogen atom, and R5 represents a C1-C3 alkylsulfonyl group, a substituted C1-C6 alkyl group, a substituted C1-C6 haloalkyl group, a substituted C1-C6 alkoxy group, or a substituted C1-C6 alkylamino group, or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: October 22, 2019Publication date: November 18, 2021Applicants: DAIICHI SANKYO COMPANY, LIMITED, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Takashi Tsuji, Yasunobu Kurosaki, Koutaro Ishibashi, Anthony B. Pinkerton
-
Patent number: 11173213Abstract: A method for producing an antibody-drug conjugate composition, comprising: (i) a step of reacting an antibody with a reducing agent in a buffer to reduce interchain disulfides, and (ii) a step of reacting drug linker intermediates with the antibody having thiol groups obtained in the step (i), wherein the reaction temperature in the step (i) is ?10° C. to 10° C., and the average number of bound drugs in the produced antibody-drug conjugate composition is 3.5 to 4.5, and the content of antibody-drug conjugates in which four drug linkers are bound to heavy-light interchain thiols, in the produced antibody-drug conjugate composition is 50% or more; and an antibody-drug conjugate composition, wherein the content of antibody-drug conjugates wherein the average number of bound drugs is 3.5 to 4.5, and the content of antibody-drug conjugates in which four drug linkers are bound to heavy-light interchain thiols, is 50% or more.Type: GrantFiled: June 28, 2016Date of Patent: November 16, 2021Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Shigeru Noguchi, Ken Sakurai, Daisuke Okajima
-
Publication number: 20210347836Abstract: To provide a novel pharmaceutical use of a peptide. A pharmaceutical composition for the treatment or prevention of retinitis pigmentosa, comprising a peptide which comprises the amino acid sequence shown in SEQ ID NO: 30 and inhibits the protease activity.Type: ApplicationFiled: June 21, 2019Publication date: November 11, 2021Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventor: Tatsuya Inoue
-
Publication number: 20210340628Abstract: A method for identifying a subject suffering from a cancer, comprising: obtaining a biological sample from the human patient diagnosed as suffering from a cancer; evaluating an amount of expression of the hTROP2 gene at mRNA level in the biological sample; evaluating an amount of expression of the SLFN11 gene at mRNA level in the biological sample, wherein the biological sample is one that is determined to have a high amount of expression of the hTROP2 gene; and identifying the human patient who provided the biological sample, wherein the biological sample is one that is determined to have a high amount of expression of the SLFN11 gene, as a subject to whom a medicament containing an anti-hTROP2 antibody is to be given.Type: ApplicationFiled: August 22, 2019Publication date: November 4, 2021Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Daisuke OKAJIMA, Satoru YASUDA, Kei ENOMOTO
-
Publication number: 20210340221Abstract: SPINK2 mutant peptide conjugates are provided that inhibit KLK5. The KLK5 inhibitory peptide conjugates are Fc fusion peptides in which, in certain embodiments, the Fc region of the fusion peptides are the Fc region of human IgG1 or a fragment thereof. The KLK5 inhibitory peptide conjugates include an amino acid sequence of one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, or 60. Pharmaceutical compositions that include the KLK5 inhibitory peptide conjugates useful for treating KLK5-related diseases are also provided.Type: ApplicationFiled: May 20, 2021Publication date: November 4, 2021Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Daisuke Nishimiya, Hidenori Yano, Hidenori Takahashi, Shinji Yamaguchi, Shiho Ofuchi
-
Publication number: 20210332149Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.Type: ApplicationFiled: July 2, 2021Publication date: October 28, 2021Applicants: Daiichi Sankyo Company, Limited, The University of TokyoInventors: Kensuke Miyake, Yusuke Murakami, Yuji Motoi, Atsuo Kanno, Toshiyuki Shimizu, Umeharu Ohto, Takaichi Shimozato, Atsushi Manno, Takashi Kagari, Jun Ishiguro, Kensuke Nakamura, Takashi Isobe
-
Patent number: 11149066Abstract: Provided is a compound that can promote angiogenesis by inhibiting the function of TSP1, and is useful for the treatment or prophylaxis of diseases such as critical limb ischemia.Type: GrantFiled: September 13, 2017Date of Patent: October 19, 2021Assignees: DAIICHI SANKYO COMPANY, LIMITED, PEPTIDREAM INC.Inventors: Takahiro Yamaguchi, Yutaka Mori, Hironao Saito, Hideki Kubota, Akihiro Furukawa, Eri Otsuka, Yutaka Ishigai, Hiroshi Ijiri, Patrick Reid
-
Publication number: 20210317498Abstract: The present invention provides an approach to enhancing the production of a foreign protein serving as a protein-based pharmaceutical product in host cells such as cultured cells derived from a mammal. The present invention provides transfected cells having a novel Hspa8 gene promoter, and a method for secreting and producing a foreign protein at high levels using the transfected cells.Type: ApplicationFiled: August 8, 2019Publication date: October 14, 2021Applicant: Daiichi Sankyo Company, LimitedInventors: Kenji Masuda, Yuto Nakazawa, Kazuhiko Watanabe, Maui Nishio, Takeshi Okumura, Koichi Nonaka
-
Publication number: 20210292292Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.Type: ApplicationFiled: March 25, 2021Publication date: September 23, 2021Applicant: Daiichi Sankyo Company, LimitedInventors: Keiji Saito, Katsuyoshi Nakajima, Toru Taniguchi, Osamu Iwamoto, Satoshi Shibuya, Yasuyuki Ogawa, Kazumasa Aoki, Nobuya Kurikawa, Shinji Tanaka, Momoko Ogitani, Eriko Kioi, Kaori Ito, Natsumi Nishihama, Tsuyoshi Mikkaichi, Wataru Saitoh
-
Publication number: 20210290777Abstract: A therapeutic agent for a metastatic brain tumor comprising, as an active component, an antibody-drug conjugate in which a drug-linker represented by the following formula (wherein A represents a connecting position to an antibody) is conjugated to the antibody via a thioether bond and/or a method of treatment for a metastatic brain tumor, comprising administering the antibody-drug conjugate to a subject in need of the treatment for a metastatic brain tumor.Type: ApplicationFiled: July 30, 2019Publication date: September 23, 2021Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Kiyoshi SUGIHARA, Chiaki ISHII
-
Publication number: 20210290775Abstract: A pharmaceutical composition, wherein an antibody-drug conjugate in which a drug-linker represented by the following formula (wherein A represents a connecting position to an antibody) is conjugated to the antibody via a thioether bond, and a tubulin inhibitor are administered in combination, and a method of treatment, wherein the antibody-drug conjugate and the tubulin inhibitor are administered in combination to a subject.Type: ApplicationFiled: August 5, 2019Publication date: September 23, 2021Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Yusuke OGITANI, Chiaki ISHII, Yasuki KAMAI, Kiyoshi SUGIHARA, Shotaro NAGASE
-
Publication number: 20210283269Abstract: A method for producing an antibody-drug conjugate in which a drug-linker represented by formula (1) (wherein A represents the connecting position to an antibody) is conjugated to the antibody via a thioether bond, wherein the method comprising the steps of: (i) reducing the antibody with a reducing agent; (ii) reacting a drug-linker intermediate with the antibody reduced in step (i); (iii) adding a reagent having a thiol group to react with the residual drug-linker intermediate in step (ii); and then (iv) removing by-products derived from the drug-linker intermediate through ultrafiltration using a buffer solution containing a salt consisting of a strong acid and a strong base, and a method for producing a pharmaceutical composition containing the antibody-drug conjugate.Type: ApplicationFiled: July 24, 2019Publication date: September 16, 2021Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Tatsuya YAMAGUCHI, Kenji SAKURATANI
-
Publication number: 20210277118Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to CD3 and uses thereof.Type: ApplicationFiled: June 20, 2019Publication date: September 9, 2021Applicant: Daiichi Sankyo Company, LimitedInventor: Thomas SPRETER VON KREUDENSTEIN
-
Publication number: 20210269454Abstract: The present invention provides a compound or a pharmaceutically acceptable salt thereof having an inhibitory action on the interaction between menin and an MLL protein. The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. wherein, in the formula (1), the dotted circle, R1, R2, R3, R4, R5, R6, R7, R8, Ring Q1, W, m and n are each as defined in the description.Type: ApplicationFiled: April 28, 2021Publication date: September 2, 2021Applicant: Daiichi Sankyo Company, LimitedInventors: Kenji Yoshikawa, Noriyasu Haginoya, Tomoaki Hamada, Ryutaro Kanada, Jun Watanabe, Yoshiko Kagoshima, Eri Tokumaru, Kenji Murata, Takayuki Baba, Mayumi Kitagawa, Akiko Kurimoto, Masashi Numata, Machiko Shiroishi, Taeko Shinozaki
-
Publication number: 20210267954Abstract: Provision of a granular preparation that contains edoxaban or a pharmacologically acceptable salt thereof, and has the property of being rapidly dissolved or suspended by the addition of water. A granular preparation comprising first granules containing (A) edoxaban or a pharmacologically acceptable salt thereof, (B) a sugar alcohol, and (C) a water-swelling additive, and second granules containing (D) 0.5 to 10% by weight of carmellose sodium with respect to the total weight of the preparation, and (E) 70 to 90% by weight of xylitol or sorbitol with respect to the total weight of the preparation.Type: ApplicationFiled: June 26, 2019Publication date: September 2, 2021Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Wolfgang SCHMID, Maren KUHLI, Christoph SCHUH